Meta-Analysis
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jun 26, 2024; 16(6): 339-354
Published online Jun 26, 2024. doi: 10.4330/wjc.v16.i6.339
Establishing delivery route-dependent safety and efficacy of living biodrug mesenchymal stem cells in heart failure patients
Muhammad Candragupta Jihwaprani, Idris Sula, Mohamed Ahmed Charbat, Khawaja Husnain Haider
Muhammad Candragupta Jihwaprani, Idris Sula, Mohamed Ahmed Charbat, Khawaja Husnain Haider, Basic Sciences, SRC, Al Bukayriyah 52736, AlQaseem, Saudi Arabia
Author contributions: Haider KH designed and produced the study and its methodology; Jihwaprani MC and Sula I performed database research and screened the extracted records against eligibility criteria; Jihwaprani MC, Sula I, and Charbat MA performed data extraction and plotting; Sula I and Charbat MA reviewed and validated the extracted data; Jihwaprani MC, Sula I, and Charbat MA performed the quality assessment of the included trials; Jihwaprani MC, Sula I, and Charbat MA conducted the statistical analysis; Jihwaprani MC, Sula I, and Charbat MA drafted the first manuscript; Haider KH contributed to the final manuscript; Jihwaprani MC, Sula I, Charbat MA, and Haider KH reviewed the final manuscript; and all authors have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Khawaja Husnain Haider, BPharm, BSc, PhD, Chairman, Full Professor, Basic Sciences, SRC, AlMadina Road, Al Bukayriyah 52736, AlQaseem, Saudi Arabia. kh.haider@sr.edu.sa
Received: February 22, 2024
Revised: May 21, 2024
Accepted: May 24, 2024
Published online: June 26, 2024
Processing time: 123 Days and 14.4 Hours
Core Tip

Core Tip: Route of delivery (RoD) remains a critical determinant of safety and efficacy in cardiac stem cell therapy, particularly in heart failure (HF) patients. HF occurs when the heart’s pumping ability is inadequate to meet the body’s metabolic needs. Mesenchymal stem cells (MSCs) are living biopharmaceuticals with unique properties that need to be administered such that they reach the target site and are retained there to participate in the repair process. This systematic review and meta-analysis of phase II randomized clinical trials determine the RoD effect on the safety and efficacy of MSCs during HF treatment.